New therapeutic options in systemic treatment of advanced cutaneous melanoma

Bibliography

• Balch CM, Gershenwald JE, Soong SJ, Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009;27:6199-206
   PubMed Web of Science ®Google Scholar
• Eggermont AM. Advances in systemic treatment of melanoma. Ann Oncol 2010;21(Suppl 7):vii339-44
   PubMedGoogle Scholar
• Eggermont AM, Schadendorf D. Melanoma and immunotherapy. Hematol Oncol Clin North Am 2009;23:547-64; ix-x
   PubMed Web of Science ®Google Scholar
• Driessens G, Kline J, Gajewski TF. Costimulatory and coinhibitory receptors in anti-tumor immunity. Immunol Rev 2009;229:126-44
   PubMed Web of Science ®Google Scholar
• Gajewski TF, Meng Y, Harlin H. Immune suppression in the tumor microenvironment. J Immunother 2006;29:233-40
   PubMed Web of Science ®Google Scholar
• Atkins MB, Lotze MT, Dutcher JP, High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 1999;17:2105-16
   PubMed Web of Science ®Google Scholar
• Hamm C, Verma S, Petrella T, Biochemotherapy for the treatment of metastatic malignant melanoma: a systematic review. Cancer Treat Rev 2008;34:145-56
   PubMed Web of Science ®Google Scholar
• Schwartzentruber DJ, Lawson DH, Richards JM, gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N Engl J Med 2011;364:2119-27
   PubMed Web of Science ®Google Scholar
• Brahmer JR, Tykodi SS, Chow LQ, Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012;366:2455-65
   PubMed Web of Science ®Google Scholar
• Hodi FS, O'Day SJ, McDermott DF, Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363:711-23
   PubMed Web of Science ®Google Scholar
• Mackiewicz A, Mackiewicz J, Wysocki PJ, Long-term survival of high-risk melanoma patients immunized with a Hyper-IL-6-modified allogeneic whole-cell vaccine after complete resection. Expert Opin Investig Drugs 2012;21:773-83
   PubMed Web of Science ®Google Scholar
• Robert C, Thomas L, Bondarenko I, Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011;364:2517-26
   PubMed Web of Science ®Google Scholar
• Topalian SL, Hodi FS, Brahmer JR, Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012;366:2443-54
   PubMed Web of Science ®Google Scholar
• Petrella TM, Tozer R, Belanger K, Interleukin-21 has activity in patients with metastatic melanoma: a phase II study. J Clin Oncol 2012;30:3396-401
   PubMed Web of Science ®Google Scholar
• Melero I, Hervas-Stubbs S, Glennie M, Immunostimulatory monoclonal antibodies for cancer therapy. Nat Rev Cancer 2007;7:95-106
   PubMed Web of Science ®Google Scholar
• Wolchok JD, Weber JS, Hamid O, Ipilimumab efficacy and safety in patients with advanced melanoma: a retrospective analysis of HLA subtype from four trials. Cancer Immun 2010;10:9
   PubMedGoogle Scholar
• Hersh EM, O'Day SJ, Powderly J, A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naive patients with advanced melanoma. Invest New Drugs 2011;29:489-98
   PubMed Web of Science ®Google Scholar
• Camacho LH, Antonia S, Sosman J, Phase I/II trial of tremelimumab in patients with metastatic melanoma. J Clin Oncol 2009;27:1075-81
   PubMed Web of Science ®Google Scholar
• Ribas A, Hauschild A, Kefford R, Phase III, open-label, randomized, comparative study of tremelimumab (CP-675,206) and chemotherapy (temozolomide [TMZ] or dacarbazine [DTIC]) in patients with advanced melanoma. J Clin Oncol 2008;26:abstract LBA9011
   Google Scholar
• Blank C, Mackensen A. Contribution of the PD-L1/PD-1 pathway to T-cell exhaustion: an update on implications for chronic infections and tumor evasion. Cancer Immunol Immunother 2007;56:739-45
   PubMed Web of Science ®Google Scholar
• Jin HT, Ahmed R, Okazaki T. Role of PD-1 in regulating T-cell immunity. Curr Top Microbiol Immunol 2011;350:17-37
   PubMed Web of Science ®Google Scholar
• Li B, VanRoey M, Wang C, Anti-programmed death-1 synergizes with granulocyte macrophage colony-stimulating factor--secreting tumor cell immunotherapy providing therapeutic benefit to mice with established tumors. Clin Cancer Res 2009;15:1623-34
   PubMed Web of Science ®Google Scholar
• Wang W, Lau R, Yu D, PD1 blockade reverses the suppression of melanoma antigen-specific CTL by CD4+ CD25(Hi) regulatory T cells. Int Immunol 2009;21:1065-77
   PubMed Web of Science ®Google Scholar
• Pilon-Thomas S, Mackay A, Vohra N, Mule JJ. Blockade of programmed death ligand 1 enhances the therapeutic efficacy of combination immunotherapy against melanoma. J Immunol 2010;184:3442-9
   PubMedGoogle Scholar
• Swick JM, Maize JCS. Molecular biology of melanoma. J Am Acad Dermatol 2012;67(5):1049-54
   PubMed Web of Science ®Google Scholar
• Thomas NE. BRAF somatic mutations in malignant melanoma and melanocytic naevi. Melanoma Res 2006;16:97-103
   PubMedGoogle Scholar
• Curtin JA, Busam K, Pinkel D, Bastian BC. Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol 2006;24:4340-6
   PubMed Web of Science ®Google Scholar
• Schoenewolf NL, Bull C, Belloni B, Sinonasal, genital and acrolentiginous melanomas show distinct characteristics of KIT expression and mutations. Eur J Cancer 2012;48:1842-52
   PubMed Web of Science ®Google Scholar
• Curtin JA, Fridlyand J, Kageshita T, Distinct sets of genetic alterations in melanoma. N Engl J Med 2005;353:2135-47
   PubMed Web of Science ®Google Scholar
• Eisen T, Marais R, Affolter A, Sorafenib and dacarbazine as first-line therapy for advanced melanoma: phase I and open-label phase II studies. Br J Cancer 2011;105:353-9
   PubMed Web of Science ®Google Scholar
• Ott PA, Hamilton A, Min C, A phase II trial of sorafenib in metastatic melanoma with tissue correlates. PLoS One 2010;5:e15588
   PubMed Web of Science ®Google Scholar
• Hauschild A, Agarwala SS, Trefzer U, Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. J Clin Oncol 2009;27:2823-30
   PubMed Web of Science ®Google Scholar
• Mangana J, Levesque MP, Karpova MB, Dummer R. Sorafenib in melanoma. Expert Opin Investig Drugs 2012;21:557-68
   PubMed Web of Science ®Google Scholar
• Flaherty KT, Puzanov I, Kim KB, Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010;363:809-19
   PubMed Web of Science ®Google Scholar
• Sosman JA, Kim KB, Schuchter L, Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 2012;366:707-14
   PubMed Web of Science ®Google Scholar
• Chapman PB, Hauschild A, Robert C, Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011;364:2507-16
   PubMed Web of Science ®Google Scholar
• Chapman PB, Hauschild A, Robert C, Updated overall survival (OS) results for BRIM-3, a phase III randomized, open-label, multicenter trial comparing BRAF inhibitor vemurafenib (vem) with dacarbazine (DTIC) in previously untreated patients with BRAFV600E-mutated melanoma. J Clin Oncol 2012;30:abstract 8502
   Web of Science ®Google Scholar
• Su F, Viros A, Milagre C, RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med 2012;366:207-15
   PubMed Web of Science ®Google Scholar
• Zimmer L, Hillen U, Livingstone E, Atypical melanocytic proliferations and new primary melanomas in patients with advanced melanoma undergoing selective BRAF inhibition. J Clin Oncol 2012;30:2375-83
   PubMed Web of Science ®Google Scholar
• Dummer R, Rinderknecht J, Goldinger SM. Ultraviolet A and photosensitivity during vemurafenib therapy. N Engl J Med 2012;366(5):480-1
   PubMed Web of Science ®Google Scholar
• Hauschild A, Grob JJ, Demidov LV, Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 2012;380:358-65
   PubMed Web of Science ®Google Scholar
• Kirkwood JM, Long GV, Trefzer U, BREAK-MB: a phase II study assessing overall intracranial response rate (OIRR) to dabrafenib (GSK2118436) in patients (pts) with BRAF V600E/K mutation-positive melanoma with brain metastases. J Clin Oncol 2012;30:abstract 8501
   Google Scholar
• Nazarian R, Shi H, Wang Q, Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 2010;468:973-7
   PubMed Web of Science ®Google Scholar
• Wagle N, Emery C, Berger MF, Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J Clin Oncol 2011;29:3085-96
   PubMed Web of Science ®Google Scholar
• Poulikakos PI, Persaud Y, Janakiraman M, RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature 2011;480:387-90
   PubMed Web of Science ®Google Scholar
• Villanueva J, Vultur A, Lee JT, Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell 2010;18:683-95
   PubMed Web of Science ®Google Scholar
• Flaherty KT, Robert C, Hersey P, Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med 2012;367:107-14
   PubMed Web of Science ®Google Scholar
• Flaherty KT, Infante JR, Daud A, Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations. N Engl J Med 2012; 367: 1694-703
   Google Scholar
• Wolchok JD, Hoos A, O'Day S, Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 2009;15:7412-20
   PubMed Web of Science ®Google Scholar
• Rubin KM. Managing immune-related adverse events to ipilimumab: a nurse's guide. Clin J Oncol Nurs 2012;16:E69-75
   PubMedGoogle Scholar
• Weber JS, Kahler KC, Hauschild A. Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol 2012;30:2691-7
   PubMed Web of Science ®Google Scholar
• Carvajal RD, Antonescu CR, Wolchok JD, KIT as a therapeutic target in metastatic melanoma. JAMA 2011;305:2327-34
   PubMed Web of Science ®Google Scholar
• Guo J, Si L, Kong Y, Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification. J Clin Oncol 2011;29:2904-9
   PubMed Web of Science ®Google Scholar
• Postow MA, Callahan MK, Barker CA, Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med 2012;366:925-31
   PubMed Web of Science ®Google Scholar